卡托普利抑制试验在原发性醛固酮增多症诊断和分型以及临床转归中的应用

R586.24; 背景 原发性醛固酮增多症(PA)作为继发性高血压中发病率最高、心脑血管危害大但手术后治愈率高的疾病,已被各大高血压指南推荐扩大筛查、早期诊断和治疗.但该类患者的确诊、分型和治疗后临床转归判定方式繁多且存在较多争议.卡托普利抑制试验(CCT)因其便捷、安全可直接用于社区、门诊,期望CCT能对PA患者进行全程管理以改善预后.目的 探究CCT对PA的诊断、分型以及临床转归的判断能力.方法 选取 2020-10-01-2022-12-30 在四川大学华西医院内分泌代谢科接受内分泌性高血压病因筛查并登记的 824 例患者为研究对象.经筛选后最终 370 例患者纳入研究,其中 123 例...

Full description

Saved in:
Bibliographic Details
Published in中国全科医学 Vol. 27; no. 21; pp. 2592 - 2599
Main Authors 谭璐, 陈涛, 高洪蛟, 陈彦希, 任艳
Format Journal Article
LanguageChinese
Published 610041 四川省成都市,四川大学华西医院内分泌代谢科肾上腺疾病中心%563000 贵州省遵义市第一人民医院内分泌代谢科 20.07.2024
Subjects
Online AccessGet full text
ISSN1007-9572
DOI10.12114/j.issn.1007-9572.2023.0839

Cover

Abstract R586.24; 背景 原发性醛固酮增多症(PA)作为继发性高血压中发病率最高、心脑血管危害大但手术后治愈率高的疾病,已被各大高血压指南推荐扩大筛查、早期诊断和治疗.但该类患者的确诊、分型和治疗后临床转归判定方式繁多且存在较多争议.卡托普利抑制试验(CCT)因其便捷、安全可直接用于社区、门诊,期望CCT能对PA患者进行全程管理以改善预后.目的 探究CCT对PA的诊断、分型以及临床转归的判断能力.方法 选取 2020-10-01-2022-12-30 在四川大学华西医院内分泌代谢科接受内分泌性高血压病因筛查并登记的 824 例患者为研究对象.经筛选后最终 370 例患者纳入研究,其中 123 例原发性高血压(EH)患者纳入EH组,247 例PA患者分别纳入单侧醛固酮瘤(APA)组 81 例、特发性醛固酮增多症(IHA)组 55 例和未分型PA(u-PA)组 111 例.比较 4 组间差异并绘制CCT后各指标及联合诊断PA的受试者工作特征(ROC)曲线,确定最佳截断值.其次绘制CCT后各指标诊断APA和IHA亚型的ROC曲线,计算ROC曲线下面积(AUC)评估CCT对APA和IHA的分型判断能力.最后根据术后临床结局将单侧肾上腺切除患者分为 3 组:未缓解组 11 例、临床改善组 27 例和临床缓解组 54 例,比较 3 组间差异并判断CCT对APA患者术后临床转归的判断能力.结果 CCT后血浆醛固酮浓度(PAC)对PA的诊断效能最高(AUC=0.921,95%CI=0.893~0.950),最佳截断值为11.7 ng/dL,灵敏度、特异度分别为84.6%和86.0%;CCT后醛固酮/肾素比值(ARR)对PA也有较好的诊断效能(AUC=0.868,95%CI=0.823~0.923),最佳截断值为 2.8(ng/dL)/(mU/L),灵敏度、特异度分别为 82.2%和 81.0%.CCT后PAC>17.0 ng/dL可协助诊断APA亚型,CCT后PAC<11.7 ng/dL同时ARR<2.8(ng/dL)/(mU/L)的患者可排除APA亚型.在接受手术治疗的患者中,有 87.2%患者经CCT后PAC<11.7 ng/dL,89.7%患者CCT后ARR<2.8(ng/dL)/(mU/L)均接近术后临床缓解水平(88.0%).结论 CCT可全程用于PA患者的诊断、分型和临床转归评价,CCT后PAC及CCT后ARR诊断PA
AbstractList R586.24; 背景 原发性醛固酮增多症(PA)作为继发性高血压中发病率最高、心脑血管危害大但手术后治愈率高的疾病,已被各大高血压指南推荐扩大筛查、早期诊断和治疗.但该类患者的确诊、分型和治疗后临床转归判定方式繁多且存在较多争议.卡托普利抑制试验(CCT)因其便捷、安全可直接用于社区、门诊,期望CCT能对PA患者进行全程管理以改善预后.目的 探究CCT对PA的诊断、分型以及临床转归的判断能力.方法 选取 2020-10-01-2022-12-30 在四川大学华西医院内分泌代谢科接受内分泌性高血压病因筛查并登记的 824 例患者为研究对象.经筛选后最终 370 例患者纳入研究,其中 123 例原发性高血压(EH)患者纳入EH组,247 例PA患者分别纳入单侧醛固酮瘤(APA)组 81 例、特发性醛固酮增多症(IHA)组 55 例和未分型PA(u-PA)组 111 例.比较 4 组间差异并绘制CCT后各指标及联合诊断PA的受试者工作特征(ROC)曲线,确定最佳截断值.其次绘制CCT后各指标诊断APA和IHA亚型的ROC曲线,计算ROC曲线下面积(AUC)评估CCT对APA和IHA的分型判断能力.最后根据术后临床结局将单侧肾上腺切除患者分为 3 组:未缓解组 11 例、临床改善组 27 例和临床缓解组 54 例,比较 3 组间差异并判断CCT对APA患者术后临床转归的判断能力.结果 CCT后血浆醛固酮浓度(PAC)对PA的诊断效能最高(AUC=0.921,95%CI=0.893~0.950),最佳截断值为11.7 ng/dL,灵敏度、特异度分别为84.6%和86.0%;CCT后醛固酮/肾素比值(ARR)对PA也有较好的诊断效能(AUC=0.868,95%CI=0.823~0.923),最佳截断值为 2.8(ng/dL)/(mU/L),灵敏度、特异度分别为 82.2%和 81.0%.CCT后PAC>17.0 ng/dL可协助诊断APA亚型,CCT后PAC<11.7 ng/dL同时ARR<2.8(ng/dL)/(mU/L)的患者可排除APA亚型.在接受手术治疗的患者中,有 87.2%患者经CCT后PAC<11.7 ng/dL,89.7%患者CCT后ARR<2.8(ng/dL)/(mU/L)均接近术后临床缓解水平(88.0%).结论 CCT可全程用于PA患者的诊断、分型和临床转归评价,CCT后PAC及CCT后ARR诊断PA
Abstract_FL Background Primary hyperaldosteronism(PA)has been recommended by numerous hypertension guidelines to expand screening,early diagnosis and treatment,as a secondary hypertension disease with the highest incidence,great cardiovascular and cerebrovascular dangers but high cure rate after surgery.However,the diagnosis,classification and clinical outcomes evaluation of these patients are varied and controversial.Captopril challenge test(CCT)is expected to provide whole-course management for PA patients because it is convenient,safe and can be used directly in the community or outpatient clinic.Objective To explore the diagnostic efficacy,classification and biochemical remission assessment of CCT in patients with PA.Methods The study population consisted of 824 patients who completed the cause screening for hypertension and were enrolled in the Department of Endocrinology and Metabolism,West China Hospital,Sichuan University from October 1 th 2020 to December 30 th 2022.After screening,247 patients with PA and 123 patients with essential hypertension(EH)were enrolled,and PA was classified into aldosterone-producing adenoma(APA,81 patients),idiopathic hyperaldosteronism(IHA,55 patients),and uncategorized PA(u-PA,111 patients).The differences among the four groups were compared and the receiver operating characteristic(ROC)curve analysis showed the diagnostic performance for the prediction of PA.Secondly,the ROC curves of each post-CCT index for APA and IHA respectively were plotted.Finally,according to the postoperative clinical outcomes,the patients with unilateral adrenal resection were divided into three groups:clinical remission,clinical improvement,and no remission group.The difference between the three groups was compared,and the cut-off point of biochemical remission of CCT in APA patients was analyzed.Results The post-CCT plasma aldosterone concentration(PAC)level had the highest diagnostic efficiency for PA(AUC=0.921,95%CI=0.893-0.950),and the cut-off was 11.7 ng/dL.The sensitivity and specificity respectively was 84.6%and 86.0%.The post-CCT aldosterone to renin ratio(ARR)also had a good diagnostic efficacy for PA(AUC=0.868,95%CI=0.823-0.923).The cut-off was 2.8(ng/dL)/(mU/L),and the sensitivity and specificity respectively were 82.2%and 81.0%.The post-CCT PAC>17 ng/dL can assist in the diagnosis of APA subtypes.When post-CCT PAC<11.7 ng/dL combined with post-CCT ARR<2.8(ng/dL)/(mU/L),APA was almost excluded.The inhibition rate of PAC after CCT and the PAC remission rate after surgery were less effective in judging the biochemical remission assessment of APA,and post-CCT PAC<11.7 ng/dL or post-CCT ARR<2.8(ng/dL)/(mU/L)could better.Among the patients receiving surgical treatment,87.2%had post-CCT PAC<11.7 ng/dL,and 89.7%had post-CCT ARR<2.8(ng/dL)/(mU/L),which was close to the postoperative clinical remission level(88.0%).Conclusion CCT can be used throughout the diagnosis,classification and clinical outcomes evaluation of PA patients.post-CCT PAC 11.7 ng/dL and post-CCT ARR 2.8(ng/dL)/(mU/L)are good cut-off for the diagnosis,and can also be used for the classification of APA and the judgment of postoperative biochemical remission.Secondly,detection before CCT has little clinical significance and can simplify the process.
Author 陈涛
谭璐
任艳
高洪蛟
陈彦希
AuthorAffiliation 610041 四川省成都市,四川大学华西医院内分泌代谢科肾上腺疾病中心%563000 贵州省遵义市第一人民医院内分泌代谢科
AuthorAffiliation_xml – name: 610041 四川省成都市,四川大学华西医院内分泌代谢科肾上腺疾病中心%563000 贵州省遵义市第一人民医院内分泌代谢科
Author_FL GAO Hongjiao
CHEN Tao
CHEN Yanxi
REN Yan
TAN Lu
Author_FL_xml – sequence: 1
  fullname: TAN Lu
– sequence: 2
  fullname: CHEN Tao
– sequence: 3
  fullname: GAO Hongjiao
– sequence: 4
  fullname: CHEN Yanxi
– sequence: 5
  fullname: REN Yan
Author_xml – sequence: 1
  fullname: 谭璐
– sequence: 2
  fullname: 陈涛
– sequence: 3
  fullname: 高洪蛟
– sequence: 4
  fullname: 陈彦希
– sequence: 5
  fullname: 任艳
BookMark eNo9UEtLAlEYvQuDzPwVLVrNdO-dO83cZUgvEFrUXmacO6LFSA3RY9WizCZLFHtpGEWRReomQib8N36j_osGilbnsTiHc6ZQxMk7AqEZgmVCCWFzOTnruo5MMNYkrmpUppgqMtYVHkHRf3cSxV03a4aSqRpReRSl4eIxOLsN7jpQfAu8ChS_Rt2r8XsJ7ltw-QDlSnD0Oi40oOGPTzrw1ITn-vDmdNT1gus2VEtQLEDzfPD9AmVv0PsE3xv1P6BfHfTaw_ox-LVhrTWNJmxjyxXxP4yh9aXFjcSKlFxbXk0sJCWXYKpLqiksYVmCmwRbaTYfDjAEsQXDptBsizAtpJQT01BNnWGNGjazOcacmgYlSgzN_qbuGY5tOJlULr-744R9qcPM9ubBfngIo-ETuvIDc8Z-tA
ClassificationCodes R586.24
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.12114/j.issn.1007-9572.2023.0839
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
DocumentTitle_FL Application of Captopril Challenge Test in Diagnosis,Classification and Clinical Outcomes of Primary Aldosteronism
EndPage 2599
ExternalDocumentID zgqkyx202421008
GrantInformation_xml – fundername: (国家重点研发计划); (四川省科技厅重点研发项目)
  funderid: (国家重点研发计划); (四川省科技厅重点研发项目)
GroupedDBID -05
2B.
4A8
92F
92I
93N
ABJNI
ACGFS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CW9
GROUPED_DOAJ
PSX
TCJ
TGQ
U1G
U5O
ID FETCH-LOGICAL-s1028-5bededde9b10dc46023ae1fe40be7fd147e40291ba5b84072af4f90092ba213
ISSN 1007-9572
IngestDate Thu May 29 04:06:51 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 21
Keywords 受试者工作特征曲线
Aldosterone to renin ratio
Primary aldosteronism
单侧醛固酮瘤
Captopril
Aldosterone-producing adenoma
卡托普利
原发性醛固酮增多症
卡托普利抑制试验
Captopril challenge test
Receiver operating characteristic curve
醛固酮/肾素比值
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-s1028-5bededde9b10dc46023ae1fe40be7fd147e40291ba5b84072af4f90092ba213
PageCount 8
ParticipantIDs wanfang_journals_zgqkyx202421008
PublicationCentury 2000
PublicationDate 2024-07-20
PublicationDateYYYYMMDD 2024-07-20
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-20
  day: 20
PublicationDecade 2020
PublicationTitle 中国全科医学
PublicationTitle_FL Chinese General Practice
PublicationYear 2024
Publisher 610041 四川省成都市,四川大学华西医院内分泌代谢科肾上腺疾病中心%563000 贵州省遵义市第一人民医院内分泌代谢科
Publisher_xml – name: 610041 四川省成都市,四川大学华西医院内分泌代谢科肾上腺疾病中心%563000 贵州省遵义市第一人民医院内分泌代谢科
SSID ssib007457159
ssj0058485
ssib007693709
ssib017477037
ssib007457160
ssib007457161
ssib001103591
ssib051368463
Score 2.3607306
Snippet R586.24; 背景...
SourceID wanfang
SourceType Aggregation Database
StartPage 2592
Title 卡托普利抑制试验在原发性醛固酮增多症诊断和分型以及临床转归中的应用
URI https://d.wanfangdata.com.cn/periodical/zgqkyx202421008
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na9RAFA-lBfEiioqfpaBzkq2ZZJKZOSZrliLoRQVvZZPdrSBUtBW0Jw9a6_pRWupXK4qiWMW2FxGp-N802_a_8L03s7upVPy6hMmbN_Peb36T5L0hmTjO8axWd_0s5aVaVQtIUHi1pAOdlXhDeCKFdCxNcb3jzNlw6II4fTG42NPXX3hr6fp4OphNbPtdyb-wCjLgFb-S_QtmO52CAMrALxyBYTj-EccsCZg6xSLOkpApzbTCgtYsSqhKsUhTVcQ0t5I4ZAnIK0wHLAHNiKkyVukyixTpJExXqFChViG-DBFJVFbQeUzKMYsjkgTWVuQxbQqCaaiSTEumpLUFDqBjIYtOUXPPGgV_oE-UJExBz4LFMYsCax1bgQR8FigBiyiBU4BMzaEAXRkd7FmiadVW1oIkAnAVQ_CCvgFCBQSiUB-Q2rEqozOICMx11i_Jvtu2BqDdbo3GoVfEQYwjVayJYssOYIkIBZjWlW0aE6yIRgXcVOXiuowncMHXcztXUohb8fETFoohJwbHjHtlyBOIQLDmEl2-hYs9e3B5bdeQOETCLXQ7y2BeIJmgVikMD7kN5KMkxFHssgpYfeLZsOq3h84rDDO5ESeWE0OvIvbQ_5CqzFQKtvAGPgAWj_adc90T1DVUB20YSQG_xmNs2mu8TDr40Y8yzSVj3qVCROZD9HXLTPgvqIWHPy7b60BuiQ7MzhX2Lmg-5m8_6wPzF0cbN8Kp3jYm8TgXFJSgkcGOkUGYNP4gZEC6G4p1XpCdGLl6-eYNnFYep70M-jwpzWsodsmI0h2OG3B2n89SBLKYntB5YfnDnBf0Q0hOutv3cSkkBACddCTgfqjobxkmsoVchX5x3IGwwznWBnjy1_Doc8jRRnV0pBC5n9_t7LIp90Bk7p97nJ6JS3udLH_4unXvWev5cj71odWcyae-bKw83vz4IH-xmD96lU_PtG6935xcyBdWN-8s529e5m_n15_e3Vhptp4s5bMP8qnJ_OX9tW_v8unm2tfP-Wpz4_un_Pvs2tel9fnb-erc-tziPudcJTlfHirZH86UxjDPKgVpvVaHeE-n3K1lIgQE1Tpv1IWb1mWjxoWEoqd5Wg1ShTtLVhuioXHburTqcX-_0zt6ZbR-wBnIZJiGmfKl9AMB-qoBD0FRC1Ndhfw58w46A3ZIhu3jZGz4J8oP_V7lsLOze-M54vSOX7tePwop0njaT_PkB0ZqCTI
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%8D%A1%E6%89%98%E6%99%AE%E5%88%A9%E6%8A%91%E5%88%B6%E8%AF%95%E9%AA%8C%E5%9C%A8%E5%8E%9F%E5%8F%91%E6%80%A7%E9%86%9B%E5%9B%BA%E9%85%AE%E5%A2%9E%E5%A4%9A%E7%97%87%E8%AF%8A%E6%96%AD%E5%92%8C%E5%88%86%E5%9E%8B%E4%BB%A5%E5%8F%8A%E4%B8%B4%E5%BA%8A%E8%BD%AC%E5%BD%92%E4%B8%AD%E7%9A%84%E5%BA%94%E7%94%A8&rft.jtitle=%E4%B8%AD%E5%9B%BD%E5%85%A8%E7%A7%91%E5%8C%BB%E5%AD%A6&rft.au=%E8%B0%AD%E7%92%90&rft.au=%E9%99%88%E6%B6%9B&rft.au=%E9%AB%98%E6%B4%AA%E8%9B%9F&rft.au=%E9%99%88%E5%BD%A6%E5%B8%8C&rft.date=2024-07-20&rft.pub=610041+%E5%9B%9B%E5%B7%9D%E7%9C%81%E6%88%90%E9%83%BD%E5%B8%82%2C%E5%9B%9B%E5%B7%9D%E5%A4%A7%E5%AD%A6%E5%8D%8E%E8%A5%BF%E5%8C%BB%E9%99%A2%E5%86%85%E5%88%86%E6%B3%8C%E4%BB%A3%E8%B0%A2%E7%A7%91%E8%82%BE%E4%B8%8A%E8%85%BA%E7%96%BE%E7%97%85%E4%B8%AD%E5%BF%83%25563000+%E8%B4%B5%E5%B7%9E%E7%9C%81%E9%81%B5%E4%B9%89%E5%B8%82%E7%AC%AC%E4%B8%80%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2%E5%86%85%E5%88%86%E6%B3%8C%E4%BB%A3%E8%B0%A2%E7%A7%91&rft.issn=1007-9572&rft.volume=27&rft.issue=21&rft.spage=2592&rft.epage=2599&rft_id=info:doi/10.12114%2Fj.issn.1007-9572.2023.0839&rft.externalDocID=zgqkyx202421008
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgqkyx%2Fzgqkyx.jpg